NICE Rejects Use of Cancer Drug Tarceva
Posted on: Tuesday, 14 November 2006, 06:00 CST
Tarceva, a lung cancer drug manufactured by Roche, may not be approved in the UK following a negative recommendation by the National Institute for Health and Clinical Excellence.
Roche has requested the approval of Tarceva as a treatment for patients who have not responded or are not able to tolerate the chemotherapy Docetaxel.
Andrew Dillon, National Institute for Health and Clinical Excellence (NICE) chief executive, said that Tarceva was no more effective at treating lung cancer than currently available cheaper alternatives. NICE also said that the product was not cost effective and therefore would not be a good use of NHS funds.
NICE said it required more information about the drug from Roche before it would make a final decision.
Tarceva has been proven to significantly prolong survival in patients with advanced-stage non-small cell lung cancer who have received at least one previous chemotherapy regimen that did not work.
In a large clinical study Tarceva produced a 45% increase in one-year survival for patients taking the drug. Tarceva is also used as a treatment for pancreatic cancer.
Source: Datamonitor
Related Articles
- Epigenomics Successfully Completes Larger Clinical Study in Early Lung Cancer Detection; Panel With Two Biomarkers Confirms Solid Performance in Larger Blood Plasma Study
- CMS Coverage Proposal for Erythropoiesis-Stimulating Agents (ESAs) Jeopardizes Cancer Clinical Practice and Patient Access
- Cancer Clinics of Excellence(TM), New National Network of Oncologists, Launches With Goal of Improving Quality of Cancer Care
- Cell Therapeutics, Inc. (CTI) Closes PGT305 (PIONEER) Lung Cancer Clinical Trial; New PGT306 Protocol to Be Submitted to FDA By Year End
- Cleveland Clinic Analysis Finds Patients With Drug-Eluting Stents Are at Increased Risk for Late Thrombosis
- Cell Therapeutics, Inc. (CTI) Temporarily Suspends Enrollment on PIONEER Lung Cancer Clinical Trial; Current Patients Continue to Be Treated
- 17,500 Participants Needed to Enroll in Major Colorectal Cancer Clinical Trials; CancerTrialsHelp.Org Launches QuickLink
- Cancer Clinic Cuts Diagnosis Time
- Major ovarian cancer clinical study announced using combination drug therapy
- Miikana Therapeutics Licenses Phase II Clinical Anti-Cancer Compound From Roche
 |
 |
User Comments (0)
RSS Feeds